Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

TOULOUSE, France, Nov. 9, 2020 /PRNewswire/ -- Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams. The study...

Read more: Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W018...

More Articles …

  1. OrbusNeich® Medical and P+F Products & Features® announce new partnership-PR Newswire APAC
  2. The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start
  3. Global Beauty & Wellness Awards announces Best Cosmetics and Hotels in the World 2020-PR Newswire APAC
  4. Centennial Property Group Announces Offering of AUD$100Million Senior Secured Loan Note Program-PR Newswire APAC
  5. ASEAN Marketing Summit 2020 -- The Biggest Marketing Summit in ASEAN is Back-PR Newswire APAC
  6. Amcor reports strong first quarter results and raises outlook for fiscal 2021-PR Newswire APAC
  7. Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy
  8. New football simulator Football for Friendship World to be released on World Football Day
  9. FP Markets recognised as 'Best FX Broker Australia' for 2020
  10. Fuji Xerox Strengthens Synergies Within Fujifilm Group to Create Growth Globally-PR Newswire APAC